Friday, September 28, 2012
BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed a Phase I study of BMN-111, an analogue of C-type natriuretic peptide, for achondroplasia, the most common form of human dwarfism.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.